Rend Al-Mondhiry and Bob Durkin to Speak at CRN’s Convergence ’25

Regulatory Group Co-Chairs Rend Al-Mondhiry and Bob Durkin have joined the roster of industry thought leaders who will take the stage at CRN’s Convergence ’25 conference in St. Louis, MO, October 8-10.

Rend’s session, “Navigating the New Regulatory Landscape,” will explore FDA’s reorganization, ongoing debates over DSHEA modernization, heightened scrutiny from FTC on advertising and substantiation, and “Make America Healthy Again.” Attendees will leave with a deeper understanding of how emerging regulations—from drug preclusion questions to state ingredient bans—could impact compliance and business strategy.

Bob’s session, “The Drug Preclusion Doctrine,” will examine the FDA’s response to two citizens’ petitions on the topic of drug preclusion. While allowing NMN to return to the market, the FDA rejected most of the petitioners’ requests that would have provided balance to the drug preclusion doctrine, which prevents supplement companies from using an ingredient that has been previously marketed or studied as a drug. Bob and his co-panelists will delve into the FDA’s response and explore its implications for the legal status of NMN and other ingredients, as well as the effects on product innovation and supplement regulation more broadly under this Administration.

For complete event details, click here.